MX2015014014A - Identificacion de la respuesta del paciente a la administracion de un modulador del receptor s1p. - Google Patents
Identificacion de la respuesta del paciente a la administracion de un modulador del receptor s1p.Info
- Publication number
- MX2015014014A MX2015014014A MX2015014014A MX2015014014A MX2015014014A MX 2015014014 A MX2015014014 A MX 2015014014A MX 2015014014 A MX2015014014 A MX 2015014014A MX 2015014014 A MX2015014014 A MX 2015014014A MX 2015014014 A MX2015014014 A MX 2015014014A
- Authority
- MX
- Mexico
- Prior art keywords
- patient
- ethyl
- benzyloxyimino
- azetidine
- trifluoromethyl
- Prior art date
Links
- 229940075993 receptor modulator Drugs 0.000 title 1
- 238000011287 therapeutic dose Methods 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- KIHYPELVXPAIDH-UHFFFAOYSA-N 1-[[4-[n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C(C)=NOCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 KIHYPELVXPAIDH-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Ecology (AREA)
- Virology (AREA)
Abstract
La invención proporciona un método de evaluación de la dosis terapéutica apropiada de ácido 1-{4-[1-(4-ciclohexil-3-trifluorome til-benciloxiimino)-etil]-2-etil-bencil}-azetidina-3-carboxílico para administrar a un paciente en necesidad del mismo, que comprende los pasos de: (i) probar si el paciente tiene o no el genotipo metabolizador pobre; y (ii) si el paciente no tiene el genotipo metabolizador pobre, administrar el ácido 1 -{4-[1 -(4-ciclohexil-3-trifluorometil-benciloxiimino)-etil]-2-etil-benc il}-azetidina-3-carboxílico, o una sal farmacéuticamente aceptable del mismo, al paciente en la dosis terapéutica estándar; y (iii) si el paciente tiene el genotipo metabolizador pobre, uno u otro (a) administrar el ácido 1-{4-[1-(4-ciclohexil-3 - trifluorometil-bencioxiimino)-etil]-2-etil-benci}-azetidina3-car boxílico, o una sal farmacéuticamente aceptable del mismo, al paciente en una dosis terapéutica por debajo de la dosis terapéutica estándar; o no administrar ácido 1-{4-[1-(4-ciclohexil -3-trifluorometil-benciloxiimino)-etil]-2-etil-bencil}-azetidina- 3-carboxílico, o una sal farmacéuticamente aceptable del mismo al paciente.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361808406P | 2013-04-04 | 2013-04-04 | |
| US201361811321P | 2013-04-12 | 2013-04-12 | |
| US201361813380P | 2013-04-18 | 2013-04-18 | |
| PCT/EP2013/058226 WO2014161606A1 (en) | 2013-04-04 | 2013-04-19 | Identifying patient response to s1p receptor modulator administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015014014A true MX2015014014A (es) | 2016-02-10 |
Family
ID=48142792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015014014A MX2015014014A (es) | 2013-04-04 | 2013-04-19 | Identificacion de la respuesta del paciente a la administracion de un modulador del receptor s1p. |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US20160046573A1 (es) |
| EP (5) | EP4556908A3 (es) |
| JP (3) | JP6240746B2 (es) |
| KR (1) | KR102166228B1 (es) |
| AR (1) | AR090929A1 (es) |
| AU (3) | AU2013385181A1 (es) |
| BR (1) | BR112015020140A8 (es) |
| CA (2) | CA2900844C (es) |
| CL (1) | CL2015002933A1 (es) |
| ES (1) | ES2941941T3 (es) |
| HK (1) | HK1213636A1 (es) |
| IL (2) | IL252497B (es) |
| MX (1) | MX2015014014A (es) |
| PH (1) | PH12015502291A1 (es) |
| RU (1) | RU2015141151A (es) |
| SG (2) | SG11201506493VA (es) |
| TN (1) | TN2015000333A1 (es) |
| TW (1) | TW201438716A (es) |
| WO (1) | WO2014161606A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE045612T2 (hu) | 2011-01-07 | 2020-01-28 | Novartis Ag | Immunszuppresszáns készítmények |
| MX2015014014A (es) * | 2013-04-04 | 2016-02-10 | Novartis Ag | Identificacion de la respuesta del paciente a la administracion de un modulador del receptor s1p. |
| AU2015332037A1 (en) * | 2014-10-16 | 2017-04-27 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| EP4445956A3 (en) | 2015-01-06 | 2024-12-04 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
| US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| EP3400211A1 (en) | 2016-01-04 | 2018-11-14 | Auspex Pharmaceuticals, Inc. | Azetidine modulators of the sphingosine 1-phosphate receptor |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| MX367667B (es) * | 2008-12-22 | 2019-08-30 | Novartis Ag | Régimen de dosificación de un agonista de los receptores de s1p. |
| RU2012117563A (ru) * | 2009-09-29 | 2013-11-10 | Новартис Аг | Режим дозирования модулятора рецептора s1p |
| MX2015014014A (es) * | 2013-04-04 | 2016-02-10 | Novartis Ag | Identificacion de la respuesta del paciente a la administracion de un modulador del receptor s1p. |
-
2013
- 2013-04-19 MX MX2015014014A patent/MX2015014014A/es unknown
- 2013-04-19 CA CA2900844A patent/CA2900844C/en active Active
- 2013-04-19 KR KR1020157026787A patent/KR102166228B1/ko not_active Expired - Fee Related
- 2013-04-19 SG SG11201506493VA patent/SG11201506493VA/en unknown
- 2013-04-19 EP EP24214581.1A patent/EP4556908A3/en active Pending
- 2013-04-19 AU AU2013385181A patent/AU2013385181A1/en not_active Abandoned
- 2013-04-19 EP EP17157993.1A patent/EP3199947A3/en not_active Withdrawn
- 2013-04-19 JP JP2016505716A patent/JP6240746B2/ja active Active
- 2013-04-19 BR BR112015020140A patent/BR112015020140A8/pt not_active IP Right Cessation
- 2013-04-19 CA CA3149287A patent/CA3149287A1/en active Pending
- 2013-04-19 SG SG10201707826RA patent/SG10201707826RA/en unknown
- 2013-04-19 EP EP19204477.4A patent/EP3647783B1/en active Active
- 2013-04-19 WO PCT/EP2013/058226 patent/WO2014161606A1/en not_active Ceased
- 2013-04-19 ES ES19204477T patent/ES2941941T3/es active Active
- 2013-04-19 EP EP13717513.9A patent/EP2981819A1/en not_active Withdrawn
- 2013-04-19 HK HK16101571.7A patent/HK1213636A1/zh unknown
- 2013-04-19 EP EP22214476.8A patent/EP4191245A3/en not_active Withdrawn
- 2013-04-19 RU RU2015141151A patent/RU2015141151A/ru unknown
- 2013-04-19 US US14/781,922 patent/US20160046573A1/en not_active Abandoned
- 2013-04-25 TW TW102114869A patent/TW201438716A/zh unknown
- 2013-05-03 AR ARP130101514A patent/AR090929A1/es unknown
-
2015
- 2015-08-03 TN TN2015000333A patent/TN2015000333A1/en unknown
- 2015-10-02 CL CL2015002933A patent/CL2015002933A1/es unknown
- 2015-10-02 PH PH12015502291A patent/PH12015502291A1/en unknown
-
2017
- 2017-04-13 AU AU2017202470A patent/AU2017202470A1/en not_active Abandoned
- 2017-05-24 IL IL252497A patent/IL252497B/en unknown
- 2017-05-25 US US15/605,277 patent/US20170320820A1/en not_active Abandoned
- 2017-11-02 JP JP2017213116A patent/JP2018076316A/ja not_active Withdrawn
-
2018
- 2018-09-20 US US16/136,630 patent/US20190135744A1/en not_active Abandoned
-
2019
- 2019-01-23 JP JP2019009208A patent/JP6934481B2/ja active Active
- 2019-03-25 AU AU2019202036A patent/AU2019202036B2/en active Active
-
2020
- 2020-06-03 US US16/891,898 patent/US20210147354A1/en not_active Abandoned
-
2021
- 2021-07-20 IL IL284999A patent/IL284999A/en unknown
-
2024
- 2024-04-09 US US18/630,271 patent/US20240270688A1/en not_active Abandoned
-
2025
- 2025-09-05 US US19/320,102 patent/US20260001839A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015014014A (es) | Identificacion de la respuesta del paciente a la administracion de un modulador del receptor s1p. | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| IN2014KN00996A (es) | ||
| MY159353A (en) | Pirfenidone treatment for patients with atypical liver function | |
| PH12012502162A1 (en) | Combination therapy | |
| SG11201808607SA (en) | Medicine obtained by combining fxr agonist and arb | |
| WO2015176062A3 (en) | Systems and methods of managing treatment of a chronic condition by symptom tracking | |
| WO2013048558A3 (en) | Methods of therapeutic monitoring of nitrogen scavenging drugs | |
| NZ593427A (en) | Dosage regimen of an s1p receptor agonist | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| WO2014074889A3 (en) | Method of determining and managing total cardiodiabetes risk | |
| MX2020001369A (es) | Sistema de analisis para el cuidado de un paciente. | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| MX2022009032A (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| UA103791C2 (uk) | Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу | |
| TN2011000457A1 (en) | Method or system using biomarkers for the monitoring of a treatment | |
| MX2016007370A (es) | Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
| WO2013110624A3 (en) | Method and system for tracing medicaments administered to an animal | |
| EP2566502A4 (en) | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION | |
| MX2019004222A (es) | Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias. | |
| RU2011108787A (ru) | Способ лечения больных красным плоским лишаем слизистой полости рта | |
| WO2009029762A3 (en) | Farnesylamine inhibitors of the visual cycle | |
| Wibberly | Intersect between the 10 essential public health services and telehealth | |
| Marak | Diffuse alveolar haemorrhage: case report | |
| Stollberger | Multiple drug interactions |